Literature DB >> 10233957

Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation.

R P Johnson1, J D Lifson, S C Czajak, K S Cole, K H Manson, R Glickman, J Yang, D C Montefiori, R Montelaro, M S Wyand, R C Desrosiers.   

Abstract

Three different deletion mutants of simian immunodeficiency virus (SIV) that vary in their levels of attenuation were tested for the ability to protect against mucosal challenge with pathogenic SIV. Four female rhesus monkeys were vaccinated by intravenous inoculation with SIVmac239Delta3, four with SIVmac239Delta3X, and four with SIVmac239Delta4. These three vaccine strains exhibit increasing levels of attenuation: Delta3 < Delta3X <Delta4. The vaccinated monkeys were challenged by vaginal exposure to uncloned, pathogenic SIVmac251 at 61 weeks after the time of vaccination. On the basis of viral RNA loads in plasma, cell-associated virus loads in peripheral blood, and CD4 cell counts, strong protective effects were observed in all three groups of vaccinated monkeys. However, the degree of protection correlated inversely with the level of attenuation; the least-attenuated strain, SIVmac239Delta3, gave the greatest protection. One monkey in the Delta3X group and two in the Delta4 group clearly became superinfected by the challenge virus, but these animals had levels of SIV RNA in plasma that were considerably lower than those of naive animals that were challenged in parallel. Protection against vaginal challenge appears easier to achieve than protection against intravenous challenge, since four other SIVmac239Delta4-vaccinated monkeys showed no protection when challenged intravenously with a much lower inoculum of the same challenge virus stock. Protection against vaginal challenge in the Delta4-vaccinated group occurred in the absence of detectable serum neutralizing activities and appeared to be associated with the development of an early SIV-specific cytotoxic-T-lymphocyte response. Our results demonstrate that mucosal protection can be achieved by systemic immunization with the highly attenuated SIVmac239Delta4 more than 1 year prior to the time of challenge.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233957      PMCID: PMC112539     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

Review 1.  The common mucosal immune system and current strategies for induction of immune responses in external secretions.

Authors:  J Mestecky
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

2.  Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

Authors:  N Almond; K Kent; M Cranage; E Rud; B Clarke; E J Stott
Journal:  Lancet       Date:  1995-05-27       Impact factor: 79.321

Review 3.  Mucosal immunity, HIV transmission, and AIDS.

Authors:  C J Miller; J R McGhee; M B Gardner
Journal:  Lab Invest       Date:  1993-02       Impact factor: 5.662

4.  A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.

Authors:  B L Lohman; M B McChesney; C J Miller; E McGowan; S M Joye; K K Van Rompay; E Reay; L Antipa; N C Pedersen; M L Marthas
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

5.  Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in vivo in the absence of an intact nef gene.

Authors:  F Kirchhoff; H W Kestler; R C Desrosiers
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Titration and characterization of two rhesus-derived SIVmac challenge stocks.

Authors:  M G Lewis; S Bellah; K McKinnon; J Yalley-Ogunro; P M Zack; W R Elkins; R C Desrosiers; G A Eddy
Journal:  AIDS Res Hum Retroviruses       Date:  1994-02       Impact factor: 2.205

7.  Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain.

Authors:  G D Ritter; M J Mulligan; S L Lydy; R W Compans
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

8.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

9.  Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV.

Authors:  M L Marthas; C J Miller; S Sutjipto; J Higgins; J Torten; B L Lohman; R E Unger; R A Ramos; H Kiyono; J R McGhee
Journal:  J Med Primatol       Date:  1992 Feb-May       Impact factor: 0.667

10.  High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection.

Authors:  M D Daniel; G P Mazzara; M A Simon; P K Sehgal; T Kodama; D L Panicali; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1994-07       Impact factor: 2.205

View more
  99 in total

1.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.

Authors:  P S Silverstein; G A Mackay; S Mukherjee; Z Li; M Piatak; J D Lifson; O Narayan; A Kumar
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.

Authors:  Barbara L Shacklett; Karen E S Shaw; Lou A Adamson; David T Wilkens; Catherine A Cox; David C Montefiori; Murray B Gardner; Pierre Sonigo; Paul A Luciw
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.

Authors:  C G Murphy; W T Lucas; R E Means; S Czajak; C L Hale; J D Lifson; A Kaur; R P Johnson; D M Knipe; R C Desrosiers
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

7.  Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Authors:  R J Gorelick; R E Benveniste; J D Lifson; J L Yovandich; W R Morton; L Kuller; B M Flynn; B A Fisher; J L Rossio; M Piatak; J W Bess; L E Henderson; L O Arthur
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

8.  Epithelial stem cells as mucosal antigen-delivering cells: A novel AIDS vaccine approach.

Authors:  Robert White; Nicole Chenciner; Gregory Bonello; Mary Salas; Philippe Blancou; Marie-Claire Gauduin
Journal:  Vaccine       Date:  2013-11-25       Impact factor: 3.641

9.  Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis.

Authors:  Juan T Borda; Xavier Alvarez; Ivanela Kondova; Pyone Aye; Meredith A Simon; Ronald C Desrosiers; Andrew A Lackner
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

10.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.